MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
+0.090
+5.36%
Pre Market: 1.820 +0.05 +2.82% 09:05 05/06 EDT
OPEN
1.680
PREV CLOSE
1.680
HIGH
1.895
LOW
1.670
VOLUME
860.69K
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.8300
MARKET CAP
285.45M
P/E (TTM)
-7.1718
1D
5D
1M
3M
1Y
5Y
NKLA, ZNGA, HIMX and RUN among notable premarket gainers
Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospit...
Seekingalpha · 38m ago
BRIEF-Trevena Inc - Trv027 Has Been Selected For An Nih Activ Trial In Covid-19 Patients.
reuters.com · 58m ago
BRIEF-Trevena Reports First Quarter 2021 Results
reuters.com · 1h ago
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopha...
GlobeNewswire · 1h ago
Trevena Q1 EPS $(0.06), Same YoY
Trevena (NASDAQ:TRVN) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.
Benzinga · 1h ago
Trevena EPS beats by $0.02, misses on revenue
Trevena (TRVN): Q1 GAAP EPS of -$0.06 beats by $0.02.Revenue of $0.21M misses by $0.57M.Cash and cash equivalents were $97.7 million as of March 31, 2021, which the Company believes
Seekingalpha · 1h ago
-- Earnings Flash (TRVN) TREVENA Posts Q1 Revenue $209,000
MT Newswires · 5h ago
Trevena to Release First Quarter 2021 Financial Results on May 6, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first...
GlobeNewswire · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRVN. Analyze the recent business situations of Trevena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRVN stock price target is 5.25 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 23.60M
% Owned: 14.64%
Shares Outstanding: 161.27M
TypeInstitutionsShares
Increased
24
3.62M
New
23
2.04M
Decreased
10
701.09K
Sold Out
10
281.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Non-Executive Chairman/Independent Director
Leon Moulder
President/Chief Executive Officer/Director
Carrie Bourdow
Chief Financial Officer/Senior Vice President
Barry Shin
Senior Vice President/Chief Compliance Officer
Scott Applebaum
Senior Vice President
Mark Demitrack
Senior Vice President
Robert Yoder
Director
Maxine Gowen
Director
Marvin Johnson
Independent Director
Scott Braunstein
Independent Director
Michael Dougherty
Independent Director
Julie McHugh
Independent Director
Jake Nunn
Independent Director
Anne Phillips
Independent Director
Barbara Yanni
No Data
About TRVN
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.